Summary of consensus recommended treatment strategies for infant leukemia subtypes
| Risk group . | Defined on the basis of . | Recommended treatment approach . |
|---|---|---|
| Infant ALL | ||
| High | KMT2A-r, younger age, late MRD clearance | Interfant induction, then intensive chemotherapy consolidation, then strongly consider HSCT (prefer non–total body irradiation based, prefer age at HSCT ≥6 mo); continued consolidation and maintenance if HSCT unavailable |
| Intermediate | KMT2A-r, older age, early MRD clearance | Interfant induction, then intensive chemotherapy consolidation and maintenance |
| Low | wt-KMT2A | Interfant induction, then identical approach as pediatric ALL (risk-stratified chemotherapy based on genetics and MRD response) |
| Infant AML | Identical approach as pediatric AML (intensive chemotherapy/gemtuzumab induction, then risk-based consolidation with chemotherapy/gemtuzumab for low risk and HSCT for high risk) | |
| Risk group . | Defined on the basis of . | Recommended treatment approach . |
|---|---|---|
| Infant ALL | ||
| High | KMT2A-r, younger age, late MRD clearance | Interfant induction, then intensive chemotherapy consolidation, then strongly consider HSCT (prefer non–total body irradiation based, prefer age at HSCT ≥6 mo); continued consolidation and maintenance if HSCT unavailable |
| Intermediate | KMT2A-r, older age, early MRD clearance | Interfant induction, then intensive chemotherapy consolidation and maintenance |
| Low | wt-KMT2A | Interfant induction, then identical approach as pediatric ALL (risk-stratified chemotherapy based on genetics and MRD response) |
| Infant AML | Identical approach as pediatric AML (intensive chemotherapy/gemtuzumab induction, then risk-based consolidation with chemotherapy/gemtuzumab for low risk and HSCT for high risk) | |